Evaluation of pharmacological activities and assessment of intraocular penetration of an ayurvedic polyherbal eye drop (Itone™) in experimental models

BMC Complementary and Alternative Medicine

Nihar Ranjan Biswas²  Hanuman Prasad Sharma¹  Alok Kumar Ravi¹  Pankaj Gupta¹  Thirumurthy Velpandian¹ 

[1] Department of Ocular Pharmacology and Pharmacy, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Room No: 634, 6th floor, New Delhi 110029, India;Department of Pharmacology, All India Institute of Medical Sciences, New Delhi 110029, India

关键词: LC-MS/MS;    Cytotoxicity;    Antioxidant;    Anticataract;    Anti-inflammatory;    Antiangiogenic;    Polyherbal;   

Others  :  1231299
DOI  :  10.1186/1472-6882-13-1

 received in 2012-08-04, accepted in 2012-12-20,  发布年份 2013

【 摘 要 】

Background

The polyherbal eye drop (Itone™) is a mixture of aqueous distillates of nineteen traditionally used ingredients that sum up to impart potency to the formulation and make it a useful adjunct in various ocular pathologies. However, as there have been no controlled experimental studies accounting to the above claim, therefore, the present study was designed to evaluate the polyherbal formulation (PHF) for antiangiogenic, anti-inflammatory, anticataract, antioxidant and cytotoxicity in addition to the evaluation of intraocular penetration of PHF in rabbit eyes using LC-MS/MS.

Materials and methods

Antiangiogenic activity of the PHF was evaluated using in ovo chick chorio-allantoic membrane (CAM) assay and in vivo cautery induced corneal neovascularization assay in rats. Anticataract potential was evaluated using steroid induced cataract in developing chick embryos, sodium selenite induced cataract in rat pups and galactose induced cataract in rats. The antioxidant activity was evaluated using di-phenyl picryl hydrazyl (DPPH) radical scavenging assay. Anti-inflammatory activity was evaluated in vitro using inhibition of LTB₄ formation in human WBCs and in vivo using carrageenan induced paw edema assay in rats. The cytotoxicity was evaluated against HeLa cancer cell lines using (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Furthermore evaluation of the intraocular penetration of the PHF was carried out in rabbit eyes via aqueous humor paracentesis and further analysis using LC-MS/MS.

Results

PHF significantly inhibited VEGF induced proliferation of new blood vessels in CAM assay and inhibited the cautery induced corneal neovascularization in rats. Additionally, PHF showed noticeable delay in the progression of cataract in the selenite and galactose induced cataract models whereby the PHF treated lenses were graded for stages II and III respectively. However, the PHF did not show any anticataract activity in the hydrocortisone induced cataract model. Moreover, PHF exhibited anti-inflammatory activity whereby it showed 39.34% inhibition of LTB₄ formation and significantly inhibited carrageenan induced paw edema in rats. Eight compounds of PHF viz. camphor, casticin, curcumin-II, quercetin, rosmarinic acid, γ-terpinene, β-pinene and dipentene exhibited transcorneal penetration in rabbit eyes.

Conclusion

The significant antiangiogenic and anti-inflammatory activities evinced by the PHF merits further investigation for ocular neovascular and inflammatory diseases in humans.

【 授权许可】

   
2013 Velpandian et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Indian Council of Medical Research: Ethical guidelines for biomedical research on human participants. New Delhi, India: Director-General, Indian Council of Medical Research; 2006:50-55.
• [2]Biswas NR, Nainiwal SK, Das GK, Langan U, Dadeya SC, Mongre PK, Ravi AK, Baidya P: Comparative randomised controlled clinical trial of a herbal eye drop with artificial tear and placebo in computer vision syndrome. J Indian Med Assoc 2003, 101(3):208-209. 212
• [3]Chatterjee PK, Bairagi D, Roy S, Majumder NK, Paul R, Bagchi S: Comparative randomised active drug controlled clinical trial of a herbal eye drop in computer vision syndrome. J Indian Med Assoc 2005, 103(7):397-398.
• [4]Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M: New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997, 34(6):455-463.
• [5]Mahoney JM, Waterbury LD: Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985, 4(5):531-535.
• [6]Velpandian T, Nirmal J, Gupta P, Vijayakumar AR, Ghose S: Evaluation of calcium dobesilate for its anti-cataract potential in experimental animal models. Methods Find Exp Clin Pharmacol 2010, 32(3):171-179.
• [7]Nishigori H, Lee JW, Lwatsuru M: An animal model for cataract research: cataract formation in developing chick embryo by glucocorticoid. Exp Eye Res 1982, 36:617-622.
• [8]Ostadalova I, Babicky A, Obenberger J: Cataract induced by administration of a single dose of sodium selenite to suckling rats. Experientia 1978, 34(2):222-223.
• [9]Sippel TO: Changes in the water, protein, and glutathione contents of the lens in the course of galactose cataract development in rats. Invest Ophthalmol 1966, 5(6):568-575.
• [10]Blois MS: Antioxidant determinations by the use of a stable free radical. Nature 1958, 181:1199-1200.
• [11]ITONE EYE DROPS: Deys. Kolkata, India: Marketing Division, Dey's Medical Stores (Mfg.) Ltd;
• [12]Das GK, Pandey RM, Biswas NR: Comparative double masked randomised placebo controlled clinical trial of a herbal eye drop preparation in trachoma and conjunctivitis. J Indian Med Assoc 1995, 93(10):383-384.
• [13]Biswas NR, Beri S, Das GK, Mongre PK: Comparative double blind multicentric randomised placebo controlled clinical trial of a herbal preparation of eye drops in some ocular ailments. J Indian Med Assoc 1996, 94(3):101-102.
• [14]Paul AK, Madan S, Gupta V: Clinical evaluation of an indigenous herbal eye drops preparation (Part I). Ind J Clin Prac 1992, 11:58-60.
• [15]Raizada JK, Mishra L: An extended clinical study with a herbal eye-drop preparation. Ind Med J 1990, 84:290-292.
• [16]Adamis AP, Aiello LP, D'Amato RA: Angiogenesis and ophthalmic disease. Angiogenesis 1999, 3(1):9-14.
• [17]Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25(4):581-611.
• [18]Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62(3):179-213.
• [19]Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56(4):549-580.
• [20]Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T: Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol 2006, 105(3):336-341.
• [21]Kuo IC: Corneal wound healing. Curr Opin Ophthalmol 2004, 15(4):311-315.
• [22]Miller JW: Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997, 151(1):13-23.
• [23]Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001, 12(4):242-249.
• [24]Luepke NP: Hen's egg chorioallantoic membrane test for irritation potential. Food Chem Toxicol 1985, 23(2):287-291.
• [25]Spielmann H: Ocular irritation. In In vitro methods in pharmaceutical research. Edited by Castell JV, Gomez-Lechon MJ. London: Academic Press; 1997:265-287.
• [26]Peebo BB, Fagerholm P, Traneus-Rockert C, Lagali N: Cellular level characterization of capillary regression in inflammatory angiogenesis using an in vivo corneal model. Angiogenesis 2011, 14(3):393-405.
• [27]Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A: The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006, 6:9. BioMed Central Full Text
• [28]Oliver A, Ciulla TA: Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am 2006, 19(3):345-351. v
• [29]Ohuchi K, Sato H, Tsurufuji S: The content of prostaglandin E and prostaglandin F2alpha in the exudate of carrageenin granuloma of rats. Biochim Biophys Acta 1976, 424(3):439-448.
• [30]Baccaglini PI, Hogan PG: Some rat sensory neurons in culture express characteristics of differentiated pain sensory cells. Proc Natl Acad Sci U S A 1983, 80(2):594-598.
• [31]Bhitre MJ, Fulmali S, Kataria M, Anwikar S, Kadri H: Anti-inflammatory activity of the fruits of piper longum Linn. Asian J Chemistry 2008, 20(6):4357-4360.
• [32]Winter CA, Risley EA, Nuss GW: Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962, 111:544-547.
• [33]Jain NK, Singh A, Kulkarni SK: Analgesic, anti-inflammatory and ulcerogenic activity of a zinc-naproxen complex in mice and rats. Pharm Pharmacol Commun 1995, 5:599-602.
• [34]Talahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA: Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci 2010, 51(3):1699-1708.
• [35]Liao T, Ke Y, Shao WH, Haribabu B, Kaplan HJ, Sun D, Shao H: Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis. Invest Ophthalmol Vis Sci 2006, 47(4):1543-1549.
• [36]Gupta SK, Selvan VK, Agrawal SS, Saxena R: Advances in pharmacological strategies for the prevention of cataract development. Indian J Ophthalmol 2009, 57(3):175-183.
• [37]Velpandian T, Mathur P, Sengupta S, Gupta SK: Preventive effect of Chyavanprash against steroid induced cataract in the developing chick embryos. Phytother Res 1998, 12:320-323.
• [38]Nishigori H: [Steroid (glucocorticoid)-induced cataract]. Yakugaku Zasshi 2006, 126(10):869-884.
• [39]Suryanarayana P, Krishnaswamy K, Reddy GB: Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis 2003, 9:223-230.
• [40]Mohan M, Gupta SK, Agnihotri S, Joshi S, Uppal RK: Anticataract action of topical quercetin and myricetin in galactosemic rats. Med Sci Res 1988, 16:685-686.
• [41]Park SU, Uddin MR, Xu H, Kim YK, Lee SY: Biotechnological applications for rosmarinic acid production in plant. African J Biotech 2008, 7:4959-4965.
• [42]Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, Byers HR: Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998, 4(6):376-383.